MX2016004212A - Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. - Google Patents

Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.

Info

Publication number
MX2016004212A
MX2016004212A MX2016004212A MX2016004212A MX2016004212A MX 2016004212 A MX2016004212 A MX 2016004212A MX 2016004212 A MX2016004212 A MX 2016004212A MX 2016004212 A MX2016004212 A MX 2016004212A MX 2016004212 A MX2016004212 A MX 2016004212A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
tor kinase
prevention
treatment
cancer characterized
Prior art date
Application number
MX2016004212A
Other languages
English (en)
Inventor
Shuichan Xu
Kristen Mae Hege
Xiaoling Wu
Zhihong Yang
Konstantinos Mavrommatis
Ellen Filvaroff
Tao Shi
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2016004212A publication Critical patent/MX2016004212A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

En la presente se proporcionan los métodos para el tratamiento y/o prevención de un cáncer en un paciente, que consisten en administrar una cantidad eficaz de un inhibidor de TOR cinasa a un paciente que tenga un cáncer caracterizado por mutación(es) o variante(s) génica(s) en particular respecto a los genes de una muestra biológica tipo nativa.
MX2016004212A 2013-10-04 2014-10-03 Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. MX2016004212A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361886785P 2013-10-04 2013-10-04
US201361907510P 2013-11-22 2013-11-22
US201462005597P 2014-05-30 2014-05-30
PCT/US2014/059043 WO2015051251A1 (en) 2013-10-04 2014-10-03 A tor kinase inhibitor in the prevention or treatment of cancer characterized by gene mutations

Publications (1)

Publication Number Publication Date
MX2016004212A true MX2016004212A (es) 2016-07-11

Family

ID=51869019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004212A MX2016004212A (es) 2013-10-04 2014-10-03 Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.

Country Status (6)

Country Link
US (1) US20150099754A1 (es)
EP (1) EP3052093A1 (es)
JP (1) JP2016540726A (es)
CN (1) CN105792816A (es)
MX (1) MX2016004212A (es)
WO (1) WO2015051251A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EA202090103A1 (ru) 2017-06-22 2020-04-24 Селджин Корпорейшн Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
CN110592213A (zh) * 2019-09-02 2019-12-20 深圳市新合生物医疗科技有限公司 预测新抗原负荷和检测基因组突变的基因panel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102686225A (zh) 2009-10-26 2012-09-19 西格诺药品有限公司 杂芳基化合物的合成和纯化方法
JP2013522215A (ja) * 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
EP3659599B1 (en) * 2011-10-19 2022-12-21 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme
WO2013075059A1 (en) * 2011-11-18 2013-05-23 Vanderbilt University Markers of triple-negative breast cancer and uses thereof

Also Published As

Publication number Publication date
JP2016540726A (ja) 2016-12-28
CN105792816A (zh) 2016-07-20
EP3052093A1 (en) 2016-08-10
WO2015051251A1 (en) 2015-04-09
US20150099754A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
AU2011328009A8 (en) Compounds and methods for treating pain
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
TW201611843A (en) Methods of treatment with arginine deiminase
IN2015DN00450A (es)
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MA40364A (fr) Polythérapie pour le traitement du cancer
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
IN2014MN01944A (es)